- Home
- SLDP vs DSGN Comparison
SLDP vs DSGN Comparison
Compare SLDP & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLDP
- DSGN
- Stock Information
- Founded
- SLDP 2011
- DSGN 2017
- Country
- SLDP United States
- DSGN United States
- Employees
- SLDP N/A
- DSGN N/A
- Industry
- SLDP Electrical Products
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- SLDP Energy
- DSGN Health Care
- Exchange
- SLDP Nasdaq
- DSGN Nasdaq
- Market Cap
- SLDP 230.9M
- DSGN 264.4M
- IPO Year
- SLDP N/A
- DSGN 2021
- Fundamental
- Price
- SLDP $1.25
- DSGN $6.02
- Analyst Decision
- SLDP Buy
- DSGN Hold
- Analyst Count
- SLDP 4
- DSGN 3
- Target Price
- SLDP $3.00
- DSGN $7.00
- AVG Volume (30 Days)
- SLDP 1.6M
- DSGN 185.6K
- Earning Date
- SLDP 11-05-2024
- DSGN 11-11-2024
- Dividend Yield
- SLDP N/A
- DSGN N/A
- EPS Growth
- SLDP N/A
- DSGN N/A
- EPS
- SLDP N/A
- DSGN N/A
- Revenue
- SLDP $19,740,000.00
- DSGN N/A
- Revenue This Year
- SLDP $15.90
- DSGN N/A
- Revenue Next Year
- SLDP $117.35
- DSGN N/A
- P/E Ratio
- SLDP N/A
- DSGN N/A
- Revenue Growth
- SLDP 25.66
- DSGN N/A
- 52 Week Low
- SLDP $1.10
- DSGN $1.96
- 52 Week High
- SLDP $2.35
- DSGN $6.91
- Technical
- Relative Strength Index (RSI)
- SLDP 41.66
- DSGN 64.12
- Support Level
- SLDP $1.23
- DSGN $4.50
- Resistance Level
- SLDP $1.28
- DSGN $5.02
- Average True Range (ATR)
- SLDP 0.04
- DSGN 0.35
- MACD
- SLDP 0.00
- DSGN 0.08
- Stochastic Oscillator
- SLDP 11.76
- DSGN 100.00
About SLDP Solid Power Inc.
Solid Power Inc is engaged in developing all-solid-state battery cell technology to enable the next generation of batteries for the EV and other markets. The company's planned business model is to license its all-solid-state battery cell designs and manufacturing know-how to top tier battery manufacturers or automotive original equipment manufacturers and to sell its sulfide-based solid electrolyte for incorporation into all-solid-state battery cells.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.